Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs.

Published

Journal Article (Review)

The current standard of care for the treatment of hepatitis C virus (HCV) consists of interferon-free direct-acting antiviral (DAA) regimens, including combinations of DAAs and fixed-dose combination pills. DAAs for HCV are likely to be heralded as one of medicine's greatest advancements. Viral eradication rates are pushing 100% for many HCV-infected populations, including patients with HIV/HCV coinfection, decompensated cirrhosis, liver and kidney transplants, and end-stage liver disease. We highlight the greatest successes of combination DAA therapies, discuss the ongoing challenges, and identify the remaining patient subgroups with unmet medical needs.

Full Text

Duke Authors

Cited Authors

  • Naggie, S; Muir, AJ

Published Date

  • January 14, 2017

Published In

Volume / Issue

  • 68 /

Start / End Page

  • 345 - 358

PubMed ID

  • 27686017

Pubmed Central ID

  • 27686017

Electronic International Standard Serial Number (EISSN)

  • 1545-326X

Digital Object Identifier (DOI)

  • 10.1146/annurev-med-052915-015720

Language

  • eng

Conference Location

  • United States